Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. [PDF]
Chakraborty D, Sinha TK, Boral S, Das A.
europepmc +1 more source
Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]
Dayer VW +4 more
europepmc +1 more source
Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study. [PDF]
Ali F +12 more
europepmc +1 more source
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme. [PDF]
Yiu CH +4 more
europepmc +1 more source
Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease. [PDF]
De Groote S +3 more
europepmc +1 more source
Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations. [PDF]
Piche SL +4 more
europepmc +1 more source
Real-world cost avoidance associated with bevacizumab biosimilar adoption in a tertiary public hospital in Ecuador: a cost-minimization and budget impact analysis. [PDF]
Rodríguez S +4 more
europepmc +1 more source
Application of Actor Network Theory to Evaluate Supply and Demand Strategies Used to Encourage International Biosimilar Uptake. [PDF]
Rieger C +4 more
europepmc +1 more source
Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.
Castle G +5 more
europepmc +1 more source
Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean. [PDF]
Espín J +4 more
europepmc +1 more source

